Bachem AG
About Bachem AG
Certifications
Categories
-
Country/Region:Switzerland
-
On CPHI since:2015
-
Certificates:2
-
Employees:1000 - 4999
Company types
Primary activities
Meet us at
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
CPHI India 2026
IICC, Yashobhoomi, Dwarka, Delhi
23 Nov 2026 - 25 Nov 2026
Products from Bachem AG (26)
-
Product Oligonucleotide CDMO
BACHEM is a global CDMO, supporting approximately 150 new chemical entity (NCE) projects across all development stages. Building on 50+ years of experience in peptides manufacturing, BACHEM has leveraged its expertise towards oligonucleotides production in 2018. Strong from technical and regulatory experie... -
Product Antazoline Hydrochloride
Fields of Application: Conjunctivitis. Antazoline Hydrochloride is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies. -
Product Antazoline Phosphate
Fields of Application: Conjunctivitis. Antazoline Hydrochloride is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies. -
Product Antazoline Sulfate
Fields of Application: Conjunctivitis. Antazoline Sulsphate is an ethylenediamine derivative with antihistaminic properties and is used in conjunction with a vasoconstrictor for ocular allergies. -
Product Carbidopa
Fields of Application: Parkinson's disease. Carbidopa, an aromatic L-amino acid decarboxylase inhibitor, which does not cross the blood-brain barrier, is routinely administered in combination with levodopa to patients with Parkinson’s disease to reduce the peripheral decarboxylation of levodopa to dopamine. -
Product Etomidate
Fields of Application: Anesthesia. Etomidate is a rapid, short acting intravenous anesthetic agent with no analgesic properties and a relative lack of significant hemodynamic and respiratory effects. -
Product Propofol
Fields of Application: Sedation, Anesthesia. Propofol is an intravenous, short acting anesthetic with rapid onset of action. -
Product Atosiban
Fields of Application: Premature labor. Atosiban is an oxytocin and vasopressin antagonist. It is used as a tocolytic in the management of preterm labor. -
Product Bivalirudin
Fields of Application: Moderate to high risk acute coronary syndromes. Percutaneous coronary intervention. Bivalirudin is a hirudin analog. It acts as a specific and reversible direct thrombin inhibitor. -
Product Buserelin
Fields of Application: Use in reproduction medicine. Advanced hormone-dependent prostate cancer Endometriosis, Central precocious puberty, Uterine myoma. Buserelin is a potent LHRH agonist. After a transient increase, continuous administration results in downregulation of LH and FSH levels followed by a su... -
Product Desmopressin Acetate
Fields of Application: Nocturnal enuresis, Central diabetes insipidus, polyuria, polydipsia, Mild and moderate forms of hemophilia A and von Willebrand disease. Desmopressin is a synthetic analog of vasopressin with low vasopressor activity. Apart from its increasing effect on water resorption by the kidne... -
Product Glucagon
Fields of Application: Hypoglycemia (due to diabetes mellitus). Glucagon opposes the action of insulin. It enhances the synthesis and mobilization of glucose in the liver.
Bachem AG Resources (10)
-
News Bachem & Novo Nordisk Redesign SPPS for Green Chemistry
In our studies in collaboration with Novo Nordisk, we set out to identify environmentally benign solvents suitable for large-scale SPPS of peptide therapeutics at ambient temperature by assessing reagent solubility, resin swelling, amino acid coupling and Fmoc-removal efficiency in a collection of REACH compatible neat solvents and selected binary solvent mixtures. These studies have shown that binary solvent mixtures are indeed viable alternatives. -
Whitepaper Microspheres and Nanoparticles for Peptide Delivery
Microparticle formulation has been successfully applied in a number of commercial products containing peptides as APIs. The use of nanoparticles for delivering proteins and peptides are still in early stages of development. Discover how Bachem is part of this technology! -
Brochure Molecular Hiving™️ Technology
The Molecular Hiving™️ technology is especially suitable for the synthesis of peptide ingredients for cosmetic products, as CMR solvents and reagents can entirely be avoided during the manufacturing process. -
Video Cost-efficient and green manufacturing of peptides thanks to Molecular Hiving technology™
Learn about the Molecular HivingTM technology, it’s scalability and the substantial advantages regarding efficiency, CMR free synthesis of peptides and greener manufacturing. -
Industry Webinar Sustainable Production of complex API
Improving the sustainability in the CDMO industry is a multi-facetted approach covering environmental, economic and social tasks while having a strong focus on these areas where a company can make the highest impact. Bachem, the leading manufacturer of peptides and oligonucleotides is a good example for using this approach successfully. By innovating for better manufacturing the company could massively reduce greenhouse gas emissions and solvent consumptions: something that is also of utmost interest when searching for a partner for large-scale production of oligonucleotides and peptides. -
Brochure Partner from Research to Marketed API
As the world’s leading company in the development and production of peptides and oligonucleotides (TIDES), Bachem is a strategic partner for Biotechnology, Pharmaceuticals, Diagnostics, Cosmetics and Life Science research. We work in close collaboration with our customers to ensure the success of their ambitious product development programs.Innovation is one of our key success factors. We are not only producing peptides and oligonucleotides in large quantities in modern industrial production facilities; we are also automating our manufacturing processes wherever possible. We have set new standards in quality, increased efficiency and reduced solvent volumes. There is an increase in the therapeutic use of oligonucleotide-based drugs. The category is also expanding from rare diseases into chronic diseases, with the potential to make a huge difference to more lives. We identified this need for oligonucleotide therapeutics to address larger-scale patient populations and indications. This is driving our commitment and journey in oligonucleotide NCEs: we want to help build a new future. -
Video AMW ¦ Customer Testimonial ¦ Why Choose Bachem?
Philipp Karbach, COO and CFO of AMW, spoke about his experience of working with Bachem:










